Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains

Hay, D; Fedorov, O; Martin, S; Singleton, D; Tallant, C; Wells, C; Picaud, S; Philpott, M; Monteiro, O; Rogers, C; Conway, S; Rooney, T; Tumber, A; Yapp, C; Filippakopoulos, P; Bunnage, M; Müller, S; Knapp, S; Schofield, C; Brennan, P

Journal article

Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains

Abstract:: Small-molecule inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking. Here, we describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300, developed from a series of 5-isoxazolyl-benzimidazoles. Our starting point was a fragment hit, which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings, benzimidazole-forming reactions, and reductive aminations. The selectivity of the lead compound against other bromodomain family members was investigated using a thermal stability assay, which revealed some inhibition of the structurally related BET family members. To address the BET selectivity issue, X-ray crystal structures of the lead compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues, selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (Kd = 21 nM) and selective, displaying 40-fold selectivity over BRD4(1). Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay. The optimized compounds are cell-active and have nanomolar affinity for CBP/p300; therefore, they should be useful in studies investigating the biological roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Hay, D., Fedorov, O., Martin, S., Singleton, D., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O., Rogers, C., Conway, S., Rooney, T., Tumber, A., Yapp, C., Filippakopoulos, P., Bunnage, M., Müller, S., Knapp, S., Schofield, C., & Brennan, P. (2014). Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains. Journal of the American Chemical Society, 136(26), 9308–9319.

MLA Style

Hay, D, et al. “Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains.” Journal of the American Chemical Society, vol. 136, no. 26, 2014, pp. 9308–19.

Chicago Style

Hay, D, O Fedorov, S Martin, et al. 2014. “Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains.” Journal of the American Chemical Society 136 (26): 9308–19.
Print